Email Facebook Twitter

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England

Alliance News

Thermo Fisher To Buy Irish Glaxo Manufacturing Site For EUR90 Million

Thu, 16th May 2019 12:26

LONDON (Alliance News) - Thermo Fisher Scientific Inc on Thursday announced a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline PLC for approximately EUR90 million in cash.

The Cork site has more than 400 employees and produces highly specialized active pharmaceutical ingredients or APIs for treating diseases including childhood cancer, depression and Parkinson's.

The site contains 270 cubic meters of reactor capacity, 10 production buildings, a research and development pilot plant, and lab infrastructure.

Thermo Fisher, a biotechnology product development company, said the site will expand capacity to meet customer demand for the development and commercial manufacturing of complex APIs. The company will also continue to produce APIs for Glaxo under a multi-year supply agreement.

The Glaxo transaction is expected to be completed by the end of 2019. The deal is subject to customary closing conditions, including regulatory approvals.

Upon completion, the site will become part of Thermo Fisher's Pharma Services business within its Laboratory Products and Services Segment.

Shares in Glaxo were up 0.1% at 1,535.31 pence on Thursday.

Copyright RTT News/dpa-AFX

Alliance News

Back to Alliance News

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.